New reagents for immunofluorescence analysis of carbazole series containing fluorinated β-dicarbonyl fragments and carboxylic substituent groups separated by spacers of different lengths from the light-gathering carb...New reagents for immunofluorescence analysis of carbazole series containing fluorinated β-dicarbonyl fragments and carboxylic substituent groups separated by spacers of different lengths from the light-gathering carbazole scaffold have been developed. The markers in complex with Eu<sup>3+</sup> ions possess stability in the aqueous phase, intense and prolonged luminescence (τ 550 - 570 μs) with characteristic emission maxima in the region of 615 nm and excitation wavelengths in the region of 380 - 390 nm, which distinguishes them from most of the analogs used. In the study of marker conjugation with streptavidin, a reagent containing 4 - 5 europium labeling complexes based on spacer-containing carbazole tetraketone was obtained. The marker-doped silicate nanoparticles exhibit intense and long-lived luminescence in the characteristic region.展开更多
Background and Objective:Intravesical administration of Bacillus Calmette-Guèrin(BCG) after transurethral resection is by far the most effective local therapy for superficial bladder cancer,the fifth most common ...Background and Objective:Intravesical administration of Bacillus Calmette-Guèrin(BCG) after transurethral resection is by far the most effective local therapy for superficial bladder cancer,the fifth most common cancer in the world.However,approximately one-third of patients fail to respond and most patients eventually relapse.In addition,there are pronounced side effects of BCG therapy,such as BCG sepsis and a high frequency of BCG-induced cystitis.This study established a novel immunotherapy through immobilization of streptavidin-tagged human IL-2(SA-hIL-2) on the biotinylated mucosal surface of bladder wall.Methods:A mouse orthotopic model of MB49 bladder cancer was established by perfusing MB49 cells into mouse bladders.The SA-hIL-2 fusion protein was immobilized on the biotinylated mucosal surface of the bladder wall.Treatment began on day 1 after MB49 implantation,once every 3 days for 6 times.Immunohistochemical assay was performed to assess the persistence of SA-hIL-2 immobilized on the biotinylated mucosal surface of the bladder wall.The mice were monitored for tumor growth and survival.On day 60 after MB49 implantation,the SA-hIL-2-cured mice,which were found to have no hematuria or palpable tumors,were challenged with wild-type MB49 cells implanted into the pretreated bladder and monitored for survival.Results:SA-hIL-2 could be immobilized efficiently and durably on the bladder mucosal surface as long as 7 days.On day 60 after MB49 implantation,9 out of 20 SA-hIL-2-treated mice survived,but all mice in PBS control group died.More importantly,5 out of 9 tumor-free mice in the SA-hIL-2 group were protected against a second intravesical wild-type MB49 tumor challenge.Conclusions:SA-hIL-2 fusion protein could significantly inhibit tumor growth and extend the survival time in the orthotopic model of MB49 bladder cancer.展开更多
The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was inves...The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was investigated. The labeling detection method was established. The biotin-streptavidin（BAS） system was introduced, and the multi-stage amplification effect of the BAS system was analyzed. It is found that the BCPDA-Eu^3＋-HBsAb-BAS fluorescent marker can emit strong fluorescence. Compared to BCPDA-Eu^3＋-HBsAb, BCPDA-Eu^3＋-HBsAb-BAS demonstrates an enhanced fluorescence intensity by over 10 times. This study provides a guidance for the next generation non-radio immunoassays in clinical diagnosis,展开更多
文摘New reagents for immunofluorescence analysis of carbazole series containing fluorinated β-dicarbonyl fragments and carboxylic substituent groups separated by spacers of different lengths from the light-gathering carbazole scaffold have been developed. The markers in complex with Eu<sup>3+</sup> ions possess stability in the aqueous phase, intense and prolonged luminescence (τ 550 - 570 μs) with characteristic emission maxima in the region of 615 nm and excitation wavelengths in the region of 380 - 390 nm, which distinguishes them from most of the analogs used. In the study of marker conjugation with streptavidin, a reagent containing 4 - 5 europium labeling complexes based on spacer-containing carbazole tetraketone was obtained. The marker-doped silicate nanoparticles exhibit intense and long-lived luminescence in the characteristic region.
基金National 863 project (No. 2006AA02Z4C4 )Sci-Tech Research Project of Baiyun district,Guangzhou (No. 2009-SZ-40)
文摘Background and Objective:Intravesical administration of Bacillus Calmette-Guèrin(BCG) after transurethral resection is by far the most effective local therapy for superficial bladder cancer,the fifth most common cancer in the world.However,approximately one-third of patients fail to respond and most patients eventually relapse.In addition,there are pronounced side effects of BCG therapy,such as BCG sepsis and a high frequency of BCG-induced cystitis.This study established a novel immunotherapy through immobilization of streptavidin-tagged human IL-2(SA-hIL-2) on the biotinylated mucosal surface of bladder wall.Methods:A mouse orthotopic model of MB49 bladder cancer was established by perfusing MB49 cells into mouse bladders.The SA-hIL-2 fusion protein was immobilized on the biotinylated mucosal surface of the bladder wall.Treatment began on day 1 after MB49 implantation,once every 3 days for 6 times.Immunohistochemical assay was performed to assess the persistence of SA-hIL-2 immobilized on the biotinylated mucosal surface of the bladder wall.The mice were monitored for tumor growth and survival.On day 60 after MB49 implantation,the SA-hIL-2-cured mice,which were found to have no hematuria or palpable tumors,were challenged with wild-type MB49 cells implanted into the pretreated bladder and monitored for survival.Results:SA-hIL-2 could be immobilized efficiently and durably on the bladder mucosal surface as long as 7 days.On day 60 after MB49 implantation,9 out of 20 SA-hIL-2-treated mice survived,but all mice in PBS control group died.More importantly,5 out of 9 tumor-free mice in the SA-hIL-2 group were protected against a second intravesical wild-type MB49 tumor challenge.Conclusions:SA-hIL-2 fusion protein could significantly inhibit tumor growth and extend the survival time in the orthotopic model of MB49 bladder cancer.
基金Supported by the National Natural Science Foundation of China（No. 81572082） and the Natural Science Foundation of Jilin Province, China（Nos.2011713, 20150414015GH, 20150204010YY）.
文摘The effect of the chelating agent 4,7-bis（chlorosulfophenyl）-1,10-phenanthroline-2,9-dicarboxylic acid （BCPDA） labeled hepatitis B surface antibodies（HBsAb） on time-resolved fluoroimmunoassays（TRFIA） was investigated. The labeling detection method was established. The biotin-streptavidin（BAS） system was introduced, and the multi-stage amplification effect of the BAS system was analyzed. It is found that the BCPDA-Eu^3＋-HBsAb-BAS fluorescent marker can emit strong fluorescence. Compared to BCPDA-Eu^3＋-HBsAb, BCPDA-Eu^3＋-HBsAb-BAS demonstrates an enhanced fluorescence intensity by over 10 times. This study provides a guidance for the next generation non-radio immunoassays in clinical diagnosis,
